Dr Chada will report directly to Intrexon’s CEO, Robert Beech and will be responsible for all aspects of the company’s pre-clinical and clinical development programs.
Dr Chada’s biotechnology experience spans more than two decades. He was most recently vice president, R&D with Introgen Research Institute and associate vice president, clinical research and development for Introgen Therapeutics where he managed clinical trials in melanoma, lung, breast, and other cancers.
Mr Beech said: “The addition of Dr Chada further strengthens our efforts to improve patient outcomes by delivering novel, controllable therapeutics for critical disease areas. Dr Chada’s extensive preclinical and clinical research experience will play a vital role in the continued success and expansion of our clinical product development activities as we move current programs forward and launch new technology initiatives.”